The antidepressant efficacy of zimelidine and maprotiline.
In a double-blind group comparison study of 39 patients with primary depressive illness zimelidine in a dose of 200 mg at night demonstrated the same order of antidepressant efficacy as maprotiline in a dose of 150 mg at night after either two or four weeks treatment measured by the amelioration or final score on the Hamilton Rating Scale (HRS) and on the Montgomery & Asberg Depression Rating Scale (MADRS). Both zimelidine and maprotiline demonstrated significant antidepressant activity at 2 weeks compared with 2 weeks prior treatment with placebo measured by amelioration on HRS (paired t 4.1 P less than 0.001, t 2.7 P less than 0.02) or MADRS (paired t 3.5 P less than 0.005, t 5.1 P less than 0.001). An item analysis of the MADRS showed significantly better sleep and appetite in the maprotiline-treated group compared with the zimelidine-treated group which is in accord with the pharmacology of the two compounds.
D000328:Adult; D000341:Affective Disorders, Psychotic / Q000188:drug therapy*; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001977:Brompheniramine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D003863:Depression / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000627:therapeutic use*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011725:Pyridines / Q000627:therapeutic use*; D013997:Time Factors; D015031:Zimeldine
D000873:Anthracenes; D000928:Antidepressive Agents; D011725:Pyridines; D008376:Maprotiline; D015031:Zimeldine; D001977:Brompheniramine